Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic dermatitis. METHODS: In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments to receive subcutaneous nemolizumab (at a dose of 0.1 mg, 0.5 mg, or 2.0 mg per kilogram of body weight) or placebo every 4 weeks or an exploratory dose of 2.0 mg of nemolizumab per kilogram every 8 weeks. The primary end point was the percentage improvement from baseline in the score on the pruritus visual-analogue scale (on which a negative change indicates improvement) at week 12. Secondary end points included changes in the score on the Eczema Area and Severity Index (EASI, on which a negative change indicates improvement), and body-surface area of atopic dermatitis. RESULTS: Of 264 patients who underwent randomization, 216 (82%) completed the study. At week 12, among the patients who received nemolizumab every 4 weeks, changes on the pruritus visual-analogue scale were -43.7% in the 0.1-mg group, -59.8% in the 0.5-mg group, and -63.1% in the 2.0-mg group, versus -20.9% in the placebo group (P<0.01 for all comparisons). Changes on the EASI were -23.0%, -42.3%, and -40.9%, respectively, in the nemolizumab groups, versus -26.6% in the placebo group. Respective changes in body-surface area affected by atopic dermatitis were -7.5%, -20.0%, and -19.4% with nemolizumab, versus -15.7% with placebo. Among the patients receiving nemolizumab every 4 weeks, treatment discontinuations occurred in 9 of 53 patients (17%) in the 0.1-mg group, in 9 of 54 (17%) in the 0.5-mg group, and in 7 of 52 (13%) in the 2.0-mg group, versus in 9 of 53 (17%) in the placebo group. CONCLUSIONS: In this phase 2 trial, nemolizumab at all monthly doses significantly improved pruritus in patients with moderate-to-severe atopic dermatitis, which showed the efficacy of targeting interleukin-31 receptor A. The limited size and length of the trial preclude conclusions regarding adverse events. (Funded by Chugai Pharmaceutical; XCIMA ClinicalTrials.gov number, NCT01986933 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase IIa study, the anti-IL-31Rα antibody nemolizumab led to a significant decrease in the pruritus sensation”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
In the citing paper
“but the overall clinical inflammation as evaluated by the body surface area (BSA), EASI and IGA scorings did not improve significantly at this time point189.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586 · cited 1×
“Japan 16 (30) 16 (30) 16 (30) 16 (31) 15 (29)”
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224 · cited 3×
“Not related to atopic dermatitis 1 (2) 1 (2) 0 1 (2) 1 (2)”
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Self-citationIL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981 · cited 1×
“4 22 (42) 18 (34) 25 (46) 25 (48) 22 (42)”
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885 · cited 1×
“(%)† 8 (15) 9 (17) 6 (11) 5 (10) 7 (13)”
Self-citationCevikbas, F., Wang, X., Akiyama, T., Kempkes, C., Savinko, T., Antal, A., Kukova, G., Buhl, T., Ikoma, A., Buddenkotte, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.048 · Cited by 804 · cited 2×
“(%)† 7 (13) 11 (21) 10 (19) 11 (21) 9 (17)”
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Self-citation
Research works printed but not linked: 2
- Oyama S, Exp Dermatol
- Lichstein KL, 2006, Sleep, 29, 232
Cited by
Items 301–400 of 588
Atopic dermatitis in skin of colour. Part 1: new discoveries in epidemiology and pathogenesis
Gan, C., Mahil, S. K., Pink, A., & Rodrigues, M. A. (2023) · Clinical and Experimental Dermatology · doi:10.1093/ced/llad111 · Cited by 15
Awosika, O., Kim, L. S., Mazhar, M., Rengifo‐Pardo, M., & Ehrlich, A. (2018) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s123329 · Cited by 20
Dupilumab para el tratamiento de la dermatitis atópica
Ferreira, S., & Torres, T. R. (2018) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2017.10.012 · Cited by 22
New Insights and Treatments in Atopic Dermatitis
Saini, S., & Pansare, M. V. (2021) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.07.005 · Cited by 17
Monoclonal antibodies for the treatment of atopic dermatitis
Renert‐Yuval, Y., & Guttman‐Yassky, E. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000455 · Cited by 18
Etiopatogenia del prurito asociado a la enfermedad renal crónica: recomponiendo las piezas del puzle
Molina, P., Ojeda, R., Blanco, A., Bezhold, G. A., Prieto‐Velasco, M., Aresté-Fosalba, N., Buades, J. M., Simó, V. E., Goicoechea, M., Pérez-Morales, R. E., et al. (2022) · Nefrología · doi:10.1016/j.nefro.2022.06.004 · Cited by 19
IL‐31 transgenic mice show reduced allergen‐induced lung inflammation
Neuper, T., Neureiter, D., Sarajlic, M., Strandt, H., Bauer, R., Schwarz, H., Suchanek, P., Korotchenko, E., Dillon, S. R., Hammerl, P., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048547 · Cited by 15
Break on Through: The Role of Innate Immunity and Barrier Defence in Atopic Dermatitis and Psoriasis
Hawerkamp, H. C., Fahy, C. M. R., Fallon, P. G., & Schwartz, C. (2022) · Skin Health and Disease · doi:10.1002/ski2.99 · Cited by 16
Kabashima, K., Matsumura, T., Komazaki, H., Kawashima, M., & The Nemolizumab-JP01 Study Group (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-00901-7 · Cited by 14
Self-citationTopical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis
Furue, M., Kadono, T., Tsuji, G., & Nakahara, T. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1397626 · Cited by 14
Self-citationT helper type 2 signatures in atopic dermatitis
Furue, M. (2018) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12023 · Cited by 16
“2 | TH2 DEVIATION IN ATOPIC DERMATITIS Compiling evidence has shown that acute AD lesions have a signifi- cantly greater number of T helper 2 (Th2) cells expressing inter- leukin‐4 (IL‐4) and IL‐13 compared with normal skin or unaffected AD skin (Figure 1).38,39 The Th2‐deviated immune response is demonstrated both in…”
BackgroundInfluentialSelf-citationInnate Immune Regulation of Dermatitis
Abreu, D., & Kim, B. (2021) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.04.011 · Cited by 15
EoE behaves as a unique Th2 disease: a narrative review
Rabinowitz, S. S., Yu, L., & Geraghty, P. M. (2022) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-22-15 · Cited by 14
Potential Aspects of the Use of Cytokines in Atopic Dermatitis
Krupka‐Olek, M., Bożek, A., Aebisher, D., Bartusik‐Aebisher, D., Cieślar, G., & Kawczyk‐Krupka, A. (2024) · Biomedicines · doi:10.3390/biomedicines12040867 · Cited by 13
Advances in Drug Delivery Systems for Atopic Dermatitis Treatment
Yang, J., Jing, L., Li, Y., Deng, D., & Miao, Y. (2024) · ChemBioChem · doi:10.1002/cbic.202400968 · Cited by 16
Dupilumab for the treatment of adolescents with atopic dermatitis
Senner, S., Seegräber, M., Frey, S., Kendziora, B., Eicher, L., & Wollenberg, A. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1801420 · Cited by 14
Self-citationTan, X. L., Thomas, B., Tan, Y., & O’Toole, E. A. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14976 · Cited by 13
English version of Japanese guidance for biologics in treating atopic dermatitis
Saeki, H., Akiyama, M., Abe, M., Igarashi, A., Imafuku, S., Ohya, Y., Katoh, N., Kameda, H., Kabashima, K., Tsunemi, Y., et al. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.16932 · Cited by 13
Self-citationAtopic dermatitis: treatment and innovations in immunotherapy
Ferrara, F., Zovi, A., Capuozzo, M., & Langella, R. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01453-8 · Cited by 13
Drugs on the Horizon for Chronic Pruritus
McEwen, M. W., Fite, E. M., Yosipovitch, G., & Patel, T. S. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.016 · Cited by 13
A Therapeutic Renaissance - Emerging Treatments for Atopic Dermatitis
Na, C. H., Baghoomian, W., & Simpson, E. L. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3515 · Cited by 13
Ditching the Itch with Anti–Type 2 Cytokine Therapies for Atopic Dermatitis
Schneider, L. C. (2017) · New England Journal of Medicine · doi:10.1056/nejme1616072 · Cited by 13
Neues in der Systemtherapie der atopischen Dermatitis
Werfel, T., Wollenberg, A., Pumnea, T., & Heratizadeh, A. (2018) · Der Hautarzt · doi:10.1007/s00105-018-4131-8 · Cited by 13
Self-citationThe emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases
GIROLOMONI, G., MAURELLI, M., & GISONDI, P. (2022) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.22.07265-6 · Cited by 12
Zhao, A., Pan, C., & Li, M. (2023) · Pediatric Investigation · doi:10.1002/ped4.12400 · Cited by 14
Zheng, J., Gu, A., Kong, L., Lu, W., Xia, J., Hu, H., & Hong, M. (2024) · ACS Omega · doi:10.1021/acsomega.3c09697 · Cited by 12
Mechanisms of Itch in Atopic Dermatitis
Kamata, Y., Tominaga, M., & Takamori, K. (2025) · Juntendō Igaku/Juntendo igaku · doi:10.14789/ejmj.jmj24-0036-r · Cited by 16
Saito, T., Iida, S., Terao, K., & Kumagai, Y. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.969 · Cited by 12
Olszewska, B., Sokołowska‐Wojdyło, M., Lakomy, J., & Nowicki, R. J. (2020) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.96260 · Cited by 13
Silverberg, J. I., Ho, S., & Collazo, R. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-01052-5 · Cited by 13
Andreasen, T. H., Christensen, M. O., Halling, A., Egeberg, A., & Thyssen, J. P. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16163 · Cited by 14
Revival of AHR Agonist for the Treatment of Atopic Dermatitis: Tapinarof
Furue, M., & Nakahara, T. (2020) · Current Treatment Options in Allergy · doi:10.1007/s40521-020-00259-7 · Cited by 13
Self-citationYokozeki, H., Murota, H., & Matsumura, T. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf045 · Cited by 11
Immunotherapy in Atopic Dermatitis
Li, W., & Man, X. (2022) · Immunotherapy · doi:10.2217/imt-2022-0054 · Cited by 12
Lerner, E. A. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.001 · Cited by 12
“Blocking the activity of interleukin-31 rapidly alleviates itch in patients with atopic dermatitis while inflammation is maintained, perhaps allowing for unlinking the immune and nervous systems (8).”
BackgroundBiologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases
Kaufman, B. P., & Alexis, A. F. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0804-8 · Cited by 11
Andrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M. (2025) · Cells · doi:10.3390/cells14181442 · Cited by 10
Blockade of OSMRβ signaling ameliorates skin lesions in a mouse model of human atopic dermatitis
Komori, T., Hisaoka, T., Kotaki, A., Iwamoto, M., Miyajima, A., Esashi, E., & Morikawa, Y. (2023) · The FASEB Journal · doi:10.1096/fj.202301529r · Cited by 11
The role of nemolizumab in the treatment of atopic dermatitis for the adult population
Prajapati, S., Flemming, J. P., Khan, D., Han, H., How, B., Rozenberg, S. S., & Feldman, S. R. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2383554 · Cited by 10
D’Auria, E., Indolfi, C., Acunzo, M., Dinardo, G., Comberiati, P., Peroni, D. G., Zuccotti, G., & del Giudice, M. M. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2452247 · Cited by 11
“Ruzicka et al. also evaluated clinical sign, showing an improvement of EASI and (Scoring Atopic Dermatitis) SCORAD after 12 weeks in the study group [67].”
Prados‐Carmona, Á., Husein‐ElAhmed, H., Navarro‐Triviño, F. J., & Ruíz‐Villaverde, R. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09075-w · Cited by 13
A new era in atopic dermatitis treatment and evolving therapeutic strategies
Honda, T. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2567133 · Cited by 11
Hassan, Z., Luvsannyam, E., Patel, D. N., Nukala, S., Puvvada, S. R., & Hamid, P. (2020) · Cureus · doi:10.7759/cureus.9901 · Cited by 10
“Therefore, blocking IL-31 may prove to be efficacious in the itchscratch cycle of AD [28].”
BackgroundTakeuchi, S., Inoue, K., Kuretake, K., Mari, O. D. A., & Furue, M. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15843 · Cited by 10
Self-citationKabashima, K., Matsumura, T., Hayakawa, Y., Kawashima, M., & for the Nemolizumab-JP01 Study Group (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2177096 · Cited by 12
Self-citationMonoclonal Antibodies for Atopic Dermatitis: Progress and Potential
Vakharia, P. P., & Silverberg, J. I. (2017) · BioDrugs · doi:10.1007/s40259-017-0241-6 · Cited by 11
Experimental Drugs with the Potential to Treat Atopic Eczema
Hon, K. E., Chan, V. P. Y., & Leung, A. K. C. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259299 · Cited by 10
Atopic dermatitis: emerging therapies
Simpson, E. L., Udkoff, J., Borok, J. F., Tom, W. L., Beck, L. A., & Eichenfield, L. F. (2017) · Seminars in Cutaneous Medicine and Surgery · doi:10.12788/j.sder.2017.0137 · Cited by 10
Hołdrowicz, A., & Woźniacka, A. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061754 · Cited by 11
“The most commonly reported TEAEs were flares of atopic dermatitis, upper respiratory tract infections, and nasopharyngitis [56,57].”
BackgroundSpencer, R. H., Kilfeather, S., Lee, E., Munera, C. L., Wen, W., Shirazian, S., Kim, B., & Menzaghi, F. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.04.035 · Cited by 14
An overview of drug discovery efforts for eczema: why is this itch so difficult to scratch?
Hon, K. E., Loo, S. K. F., Leung, A. K. C., Li, J. T. S., & Lee, V. W. Y. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1722639 · Cited by 9
“itus in patients with moderate-to-severe AD [87].”
BackgroundMethodInfluentialEmerging drugs for the treatment of chronic pruritic diseases
Fourzali, K. M., Golpanian, R. S., & Yosipovitch, G. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1801632 · Cited by 10
Clinical trials of antibody drugs in the treatments of atopic dermatitis
Zhou, G., Huang, Y., & Chu, M. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1229539 · Cited by 9
“7% Injection-site reaction, upper respiratory tract infection (33) (34) (35)”
BackgroundGB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy
Deng, F., Qiu, Y., Zhang, X., Guo, N., Hu, J., Yang, W., Shang, W., Liu, B., & Qin, S. (2024) · Antibody Therapeutics · doi:10.1093/abt/tbad032 · Cited by 9
Atopic Dermatitis and Type 2 Immune Deviation
Furue, M., Ulzii, D., Vu, Y. H., Tsuji, G., Kido‐Nakahara, M., & Nakahara, T. (2019) · Current Treatment Options in Allergy · doi:10.1007/s40521-019-00219-w · Cited by 10
Self-citationPathophysiology and Management of Atopic Dermatitis: A Laconic Review
Kumar, P., Sharma, D. K., & Ashawat, M. S. (2019) · Current Drug Therapy · doi:10.2174/1574885514666190828152316 · Cited by 9
Adams, R., Colmont, C. S., Mukhtar, A., Morgan, H. J., & Patel, G. K. (2019) · Clinical and Experimental Dermatology · doi:10.1111/ced.14059 · Cited by 9
Eczematous dermatitis in primary immunodeficiencies: A review of cutaneous clues to diagnosis
Hoskins, S., Skoda‐Smith, S., Torgerson, T. R., & Boos, M. D. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.108330 · Cited by 9
Treatment of atopic dermatitis with biologics and Janus kinase inhibitors
Thyssen, J. P., & Thomsen, S. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00717-0 · Cited by 9
Immunological Targets of Biologic Drugs in Allergic Skin Diseases in Children
Filippo, P. D., Russo, D., Attanasi, M., Pillo, S. D., & Chiarelli, F. (2021) · Biomedicines · doi:10.3390/biomedicines9111615 · Cited by 10
Treatments for chronic pruritus outside of the box
Metz, M. (2019) · Experimental Dermatology · doi:10.1111/exd.14007 · Cited by 10
Safety considerations when using drugs to treat pruritus
Fourzali, K. M., & Yosipovitch, G. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1728252 · Cited by 9
“Specifically, nemolizumab, targeting the IL-31 receptor, demonstrates improvement in pruritus scores in those with AD and prurigo nodularis [96,97].”
BackgroundSingto, T., Filor, V., Vidak, J., Klopfleisch, R., & Bäumer, W. (2024) · BMC Immunology · doi:10.1186/s12865-024-00604-4 · Cited by 8
Sensory sentinels: Neuroimmune detection and food allergy
Matatia, P. R., Christian, E., & Sokol, C. L. (2024) · Immunological Reviews · doi:10.1111/imr.13375 · Cited by 10
Sugiyama, A., Yano‐Takamori, A., Kojima, K., Nishie, H., Nishimura, M., Hiramoto, T., & Nakahara, T. (2025) · The Journal of Dermatology · doi:10.1111/1346-8138.17626 · Cited by 8
Targeted therapies and precision medicine for inflammatory skin diseases
Gilliet, M. F. (2019) · European Journal of Dermatology · doi:10.1684/ejd.2019.3539 · Cited by 8
Emerging treatments for atopic dermatitis
Katoh, N. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15504 · Cited by 12
Olszewska, B., Żawrocki, A., Gleń, J., Lakomy, J., Karczewska, J., Zabłotna, M., Malek, M., Jankau, J. A., Lange, M., Biernat, W., et al. (2021) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.100824 · Cited by 9
LeBeau, P. K., Lockhart, A., Togias, A. G., Sandel, M. T., Gereige, J., Bacharier, L. B., Lovinsky‐Desir, S., Wood, R. A., James, R. L., Busse, W. W., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.022 · Cited by 9
Evolving Landscape of Systemic Therapy for Pediatric Atopic Dermatitis
Lockhart, M. K., & Siegfried, E. C. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2021.12.002 · Cited by 8
Blom, T., & Rustemeyer, T. (2022) · Journal of Wound Ostomy and Continence Nursing · doi:10.1097/won.0000000000000903 · Cited by 8
The Acari Hypothesis, III: Atopic Dermatitis
Retzinger, A. C., & Retzinger, G. S. (2022) · Pathogens · doi:10.3390/pathogens11101083 · Cited by 8
Perforating dermatosis in a patient on haemodialysis successfully treated with nemolizumab
Ohmori, S., & Sawada, Y. (2023) · Clinical and Experimental Dermatology · doi:10.1093/ced/llad119 · Cited by 8
New and Potential Treatments for Atopic Dermatitis: Biologicals and Small Molecules
Sánchez‐Borges, M., Capriles-Hulett, A., Ortega‐Martell, J. A., & Ansotegui, I. J. (2019) · Current Allergy and Asthma Reports · doi:10.1007/s11882-019-0849-3 · Cited by 10
Nusbaum, K. B., Fleischer, S., & Fleischer, A. B. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1986204 · Cited by 10
Recent Advances of Basophils in Pruritic Skin Diseases
Liu, W., Xu, R., & Wang, F. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.12.005 · Cited by 7
Production of IL-31 in CD45RO+CLA+H4R+ T Cells in Atopic Dermatitis
Bang, C. H., Song, J. Y., Song, Y. M., Lee, J. H., Park, Y. M., & Lee, J. Y. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091976 · Cited by 7
Divergent in situ expression of IL ‐31 and IL‐31RA between bullous pemphigoid and pemphigus vulgaris
Ergün, E. Z., Aoki, R., Horváth, O. N., Hartmann, D., Satoh, T. K., Calabrese, L., Aksu, A. E. K., Gürel, M. S., Manav, V., Flaig, M. J., et al. (2023) · Experimental Dermatology · doi:10.1111/exd.14842 · Cited by 7
Self-citationExisting and Emerging Therapies for Cutaneous T-Cell Lymphoma
Van-de-Velde, V., & Zhou, Y. (2019) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475419840629 · Cited by 7
Interleukin 31 and targeted vaccination in a case series of six horses with chronic pruritus
Fettelschoss, V., Olomski, F., Birkmann, K., Kündig, T. M., Bergvall, K. E., & Fettelschoss‐Gabriel, A. (2020) · Equine Veterinary Education · doi:10.1111/eve.13408 · Cited by 7
“The clinical studies in both species have revealed that the antibodies significantly reduced pruritus and to date no adverse reactions have been recorded (Michels et al. 2016; Moyaert et al. 2017; Ruzicka et al. 2017; Tamamoto-Mochizuki et al. 2019).”
BackgroundTargeted inhibition of EPAS1-driven IL-31 production by a small-molecule compound
Kamikaseda, Y., Uruno, T., Kunimura, K., Harada, A., Saiki, K., Oisaki, K., Sakata, D., Nakahara, T., Kido‐Nakahara, M., Kanai, M., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.03.029 · Cited by 7
Self-citationEmerging systemic therapies for atopic dermatitis: biologics
Nusbaum, K. B., Nguyen, C., & Fleischer, A. B. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1836314 · Cited by 7
“0mg/kg every 8 weeks, or placebo every 4weeks for 12-weeks (1:1:1:1:1) (15).”
BackgroundLeveraging the nice face of Janus kinase inhibition—ruxolitinib cream in atopic dermatitis
Bieber, T. R. M. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.12.012 · Cited by 7
Prurigo nodularis forecast: Light type 2 inflammation with high chances of fibrosis
Conrad, C., & Schlapbach, C. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.11.003 · Cited by 7
Capturing patient-reported sleep disturbance in atopic dermatitis clinical trials
Dias-Barbosa, C., Silverberg, J. I., Ständer, S., Rodriguez, D. N., Fofana, F., Filipenko, D., Ulianov, L., Piketty, C., & Puelles, J. (2024) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-024-00751-7 · Cited by 6
The future of topical JAK inhibitors in the treatment of atopic dermatitis
Mazgaj, J., Kotewicz, M., Jaworek, A., & Szepietowski, J. C. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2465869 · Cited by 7
Sato, E., Arima, H., Tsutsui, K., Shimizu, H., Ito, K., Iwata, M., & Imafuku, S. (2025) · Experimental Dermatology · doi:10.1111/exd.70120 · Cited by 7
“However, various adverse events have been reported in some patients treated with nemolizumab, including the exacerbation of AD in the form of symptoms such as the emergence of new erythema and an increased eosinophil count [2, 4, 7, 8].”
Biologicals in the Treatment of Pediatric Atopic Diseases
Hove, M. V., Neininger, M. P., Bertsche, T., & Prenzel, F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_307 · Cited by 8
Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond
David, E., Hawkins, K. A., Shokrian, N., DUCA, E. D., & Guttman‐Yassky, E. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2368192 · Cited by 7
Small-Molecule-Based Immunotherapy for Immunologically Mediated Skin Conditions
Sernicola, A., Russo, I., & Alaibac, M. (2020) · Immunotherapy · doi:10.2217/imt-2019-0190 · Cited by 8
Scholl, I. M., Drucker, A. M., Flohr, C., & Gerbens, L. A. A. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.10.052 · Cited by 9
Exploring itch in hidradenitis suppurativa with lessons from atopic dermatitis and psoriasis
Trupiano, N. E., Young, K. Z., Echuri, H., Maghfour, J., Orenstein, L. A. V., & Hamzavi, I. H. (2025) · The Journal of Dermatology · doi:10.1111/1346-8138.17622 · Cited by 5
Biologics for Itch: IL-4/IL-13, IL-31, IL-17, and IL-23 Antagonists
Reich, A., Szczęch, J., & Samotij, D. (2017) · Current Dermatology Reports · doi:10.1007/s13671-017-0204-7 · Cited by 6
Systemic treatments in atopic dermatitis in children
Gürel, D. İ., Soyer, Ö., & Şahiner, Ü. M. (2023) · The Turkish Journal of Pediatrics · doi:10.24953/turkjped.2023.203 · Cited by 8
Modulation of NR1 receptor by CaMKIIα plays an important role in chronic itch development in mice
Li, N., Tang, Y., Huang, S., Liu, X.-T., Zeng, L., Li, H., & Wan, L. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.02.011 · Cited by 5
Omalizumab for severe atopic dermatitis in 4- to 19-year-olds: the ADAPT RCT
Chan, S., Cro, S., Cornelius, V. R., Jahan, R., Radulović, S., & Lack, G. (2022) · Efficacy and Mechanism Evaluation · doi:10.3310/wcxn5739 · Cited by 7
Therapy with anti-interleukin-31 receptor A antibody for atopic dermatitis
Fioranelli, M., Roccia, M. G., & Lotti, T. (2017) · Dermatologic Therapy · doi:10.1111/dth.12490 · Cited by 5
Recent Insights in Atopic Dermatitis Pathogenesis, Treatment, and Disease Impact
Nguyen, M., Pona, A., Kolli, S., Feldman, S., & Strowd, L. C. (2019) · Journal of Dermatology & Dermatologic Surgery · doi:10.4103/jdds.jdds_15_19 · Cited by 5
van Santen, S., Out‐Luiting, J. J., Zoutman, W. H., Quint, K. D., Willemze, R., Vermeer, M. H., & Tensen, C. P. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101007 · Cited by 6
The evolving landscape of immunotherapy for the treatment of allergic conditions
Pandya, A., Adah, E., Jones, B. L., & Chevalier, R. L. (2023) · Clinical and Translational Science · doi:10.1111/cts.13546 · Cited by 6
Metadata
- Authors
- Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., Stewart, J., & Kabashima, K.
- Affiliations
- Jagiellonian University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-02
- Volume
- 376
- Issue
- 9
- Pages
- 826-835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2593200577
- Cited by
- 592
- References
- 40
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 49 · 2023: 41 · 2022: 45 · 2021: 87 · 2020: 73 · 2019: 95 · 2018: 82 · 2017: 52
- FWCI
- 94.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, nemolizumab, pruritus, Eczema Area and Severity Index, body surface area involvement, treatment efficacy and safety, dose comparison, treatment discontinuation, adverse events, moderate-to-severe atopic dermatitis, adults, biologic therapy
- MeSH terms
- Adult, Dermatitis, Atopic, Edema, Female, Humans, Male, Middle Aged, Pruritus, Receptors, Interleukin, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.